Daniel Larcombe-Young
YOU?
Author Swipe
View article: GLUT5 armouring enhances adoptive T cell therapy anti-tumour activity under glucose-limiting conditions
GLUT5 armouring enhances adoptive T cell therapy anti-tumour activity under glucose-limiting conditions Open
Cancer immunotherapy with engineered T cells has become a standard treatment for certain hematologic cancers. However, clinical trial outcomes for solid tumours are significantly lagging. A primary challenge in solid tumours is the lack of…
View article: GLUT5 armouring enhances adoptive T-cell therapy anti-tumour activity under glucose-limiting conditions
GLUT5 armouring enhances adoptive T-cell therapy anti-tumour activity under glucose-limiting conditions Open
Background Cancer immunotherapy with engineered T cells has become a standard treatment for certain haematological cancers. However, clinical trial outcomes for solid tumours are significantly lagging. A primary challenge in solid tumours …
View article: Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells
Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells Open
NKG2D ligands (NKG2DLs) are broadly expressed in cancer. To target these, we describe an adaptor chimeric antigen receptor (CAR) termed NKG2D/Dap10-12. Herein, T cells are engineered to co-express NKG2D with a fusion protein that comprises…
View article: Metabolic armouring of CAR and TCR T cells
Metabolic armouring of CAR and TCR T cells Open
Cancer immune therapy with engineered immune cells is standard of care in certain hematologic malignancies. However, solid tumor outcomes in clinical trials are lagging significantly behind. Engineered T cells face a myriad of challenges w…
View article: Engineering a Dual Specificity γδ T-Cell Receptor for Cancer Immunotherapy
Engineering a Dual Specificity γδ T-Cell Receptor for Cancer Immunotherapy Open
γδ T-cells provide immune surveillance against cancer, straddling both innate and adaptive immunity. G115 is a clonal γδ T-cell receptor (TCR) of the Vγ9Vδ2 subtype which can confer responsiveness to phosphoantigens (PAgs) when genetically…
View article: Supplementary figures from Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer
Supplementary figures from Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer Open
Supplementary figures
View article: Supplementary figures from Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer
Supplementary figures from Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer Open
Supplementary figures
View article: Data from Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer
Data from Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer Open
Purpose: Highly aggressive triple-negative breast cancers (TNBCs) lack validated therapeutic targets and have high risk of metastatic disease. Folate receptor alpha (FRα) is a central mediator of cell growth regulation that could serve as …
View article: Supplementary data from Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer
Supplementary data from Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer Open
Supplementary Figure Legends, Materials and Methods
View article: Data from Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer
Data from Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer Open
Purpose: Highly aggressive triple-negative breast cancers (TNBCs) lack validated therapeutic targets and have high risk of metastatic disease. Folate receptor alpha (FRα) is a central mediator of cell growth regulation that could serve as …
View article: Supplementary data from Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer
Supplementary data from Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer Open
Supplementary Figure Legends, Materials and Methods
View article: Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation
Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation Open
Co-stimulation is critical to the function of chimeric antigen receptor (CAR) T-cells. Previously, we demonstrated that dual co-stimulation can be effectively harnessed by a parallel (p)CAR architecture in which a CD28-containing second ge…
View article: Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors
Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors Open
Second generation (2G) chimeric antigen receptors (CARs) contain a CD28 or 41BB co-stimulatory endodomain and elicit remarkable efficacy in hematological malignancies. Third generation (3G) CARs extend this linear blueprint by fusing both …
View article: PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer
PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer Open
Squamous cell carcinoma of head and neck (SCCHN) is the eighth most common cancer in the UK [1], with a 4-year survival rate of only 56%. Currently, there are approximately 12,200 new cases and 4,0...
View article: Hypoxia-Sensing CAR T-Cells Provide Safety and Efficacy in Treating Solid Tumors
Hypoxia-Sensing CAR T-Cells Provide Safety and Efficacy in Treating Solid Tumors Open
There has been significant interest in the prospects of chimeric antigen receptor (CAR) T-cell therapy in the treatment of solid malignancies, and multiple clinical trials are in progress 1 . However, the scope of these trials has been res…
View article: Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer
Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer Open
Purpose: Highly aggressive triple-negative breast cancers (TNBCs) lack validated therapeutic targets and have high risk of metastatic disease. Folate receptor alpha (FRα) is a central mediator of cell growth regulation that could serve as …